Patents by Inventor Martin E. Hemler

Martin E. Hemler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for inhibiting DHHC-type palmitoyltransferases for cancer treatment
    Patent number: 11384126
    Abstract: The present invention relates to compositions and methods for inhibiting DHHC3 palmitoyltransferase for treating cancer. Described herein, are methods of inhibiting expression or activity of programmed death-ligand 1 (PD-L1) in a cell of a subject, e.g., a human subject, in need thereof are carried out by administering to the subject an effective amount of a palmitoyltransferase inhibitor, thereby inhibiting the expression or activity of PD-L1 in the subject. The palmitoyltransferase comprises an Asp-His-His-Cys motif (DHHC)-type protein. Exemplary DHHC-type proteins include DHHC3, DHHC5, DHHC7, and DHHC17.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: July 12, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Chandan Sharma, Martin E. Hemler
  • COMPOSITIONS AND METHODS FOR INHIBITING DHHC-TYPE PALMITOYLTRANSFERASES FOR CANCER TREATMENT
    Publication number: 20210032298
    Abstract: The present invention relates to compositions and methods for inhibiting DHHC3 palmitoyltransferase for treating cancer. Described herein, are methods of inhibiting expression or activity of programmed death-ligand 1 (PD-L1) in a cell of a subject, e.g., a human subject, in need thereof are carried out by administering to the subject an effective amount of a palmitoyltransferase inhibitor, thereby inhibiting the expression or activity of PD-L1 in the subject. The palmitoyltransferase comprises an Asp-His-His-Cys motif (DHHC)-type protein. Exemplary DHHC-type proteins include DHHC3, DHHC5, DHHC7, and DHHC17.
    Type: Application
    Filed: November 30, 2018
    Publication date: February 4, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Chandan Sharma, Martin E. Hemler
  • VLA proteins
    Patent number: 5583203
    Abstract: Three new and distinct heterodimers in the very late antigen (VLA) protein family are disclosed, namely VLA-3, VLA-4 and VLA-5, as well as monoclonal antibodies therefor. The N-terminal amino acid sequence for each of the VLA .alpha. subunits is also disclosed.
    Type: Grant
    Filed: March 7, 1995
    Date of Patent: December 10, 1996
    Assignee: Dana-Farber Cancer Institute
    Inventors: Martin E. Hemler, Yoshikazu Takada
  • .beta..sub.5 protein and DNA encoding the same
    Patent number: 5527679
    Abstract: In accordance with the present invention, a cDNA clone encoding a new human .beta. subunit which was designated .beta..sub.5 was found. Probes for this nucleotide sequence are described. In addition, the .beta..sub.5 protein, its associated subunit and its cell distribution were characterized. In another embodiment, this invention relates to assays for detecting this protein. .beta..sub.5 subunit was found present on carcinomas, but absent from lymphoid cells. Consequently, this protein can be used to determine the presence of carcinoma.
    Type: Grant
    Filed: April 27, 1993
    Date of Patent: June 18, 1996
    Assignee: Dana Farber Cancer Institute
    Inventors: Martin E. Hemler, Hemavathi Ramaswamy